NO20002590L - Formulations comprising dissolved paroxetine - Google Patents
Formulations comprising dissolved paroxetineInfo
- Publication number
- NO20002590L NO20002590L NO20002590A NO20002590A NO20002590L NO 20002590 L NO20002590 L NO 20002590L NO 20002590 A NO20002590 A NO 20002590A NO 20002590 A NO20002590 A NO 20002590A NO 20002590 L NO20002590 L NO 20002590L
- Authority
- NO
- Norway
- Prior art keywords
- paroxetine
- solid
- formulations
- solutions
- dissolved
- Prior art date
Links
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title abstract 5
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title abstract 5
- 229960002296 paroxetine Drugs 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 1
- 239000012051 hydrophobic carrier Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Det beskrives farmasøytiske formuleringer av paroxetin, hvor paroxetinet er i løsning i en fast, halvfast eller flytende bærer. Løsningene benyttes til fylling av kapsler, eller selvbærende faste løsninger formes til faste doseringsformer som tabletter eller pellets. Det beskrives også nye flytende formuleringer, hvor et solubiliseringsmiddel benyttes til å solubilisere paroxetin i oljer og/eller lipider, samt fremgangsmåter for å unngå at andre paroxetinformer omdannes til hemihydratet, ved bruk av vannfrie eller hydrofobe bærere eller hjelpestoffer.Pharmaceutical formulations of paroxetine are disclosed, wherein the paroxetine is in solution in a solid, semi-solid or liquid carrier. The solutions are used to fill capsules, or self-supporting solid solutions are formed into solid dosage forms such as tablets or pellets. Also described are new liquid formulations, wherein a solubilizing agent is used to solubilize paroxetine in oils and / or lipids, and methods for preventing other paroxetine informants from being converted to the hemihydrate, using anhydrous or hydrophobic carriers or excipients.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9724544.3A GB9724544D0 (en) | 1997-11-21 | 1997-11-21 | Novel Formulation |
| PCT/GB1998/003471 WO1999026625A1 (en) | 1997-11-21 | 1998-11-18 | Formulations comprising dissolved paroxetine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002590D0 NO20002590D0 (en) | 2000-05-19 |
| NO20002590L true NO20002590L (en) | 2000-07-19 |
Family
ID=10822374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002590A NO20002590L (en) | 1997-11-21 | 2000-05-19 | Formulations comprising dissolved paroxetine |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1033986A1 (en) |
| JP (1) | JP2001523718A (en) |
| KR (1) | KR20010032320A (en) |
| CN (1) | CN1279608A (en) |
| AP (1) | AP2000001821A0 (en) |
| AR (1) | AR015485A1 (en) |
| AU (1) | AU1168099A (en) |
| BG (1) | BG104527A (en) |
| BR (1) | BR9814220A (en) |
| CO (1) | CO4970832A1 (en) |
| DZ (1) | DZ2658A1 (en) |
| EA (1) | EA200000552A1 (en) |
| GB (1) | GB9724544D0 (en) |
| HU (1) | HUP0100580A3 (en) |
| IL (1) | IL136106A0 (en) |
| MA (1) | MA24704A1 (en) |
| NO (1) | NO20002590L (en) |
| OA (1) | OA11385A (en) |
| PE (1) | PE20000381A1 (en) |
| PL (1) | PL340555A1 (en) |
| SK (1) | SK7342000A3 (en) |
| TR (1) | TR200001423T2 (en) |
| WO (1) | WO1999026625A1 (en) |
| ZA (1) | ZA9810637B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810180D0 (en) * | 1998-05-13 | 1998-07-08 | Smithkline Beecham Plc | Novel formulation |
| JP4854115B2 (en) * | 1999-03-12 | 2012-01-18 | エイシカ ファーマシューティカルス リミテッド | Stable formulation for anhydrous paroxetine |
| KR100759159B1 (en) | 1999-07-01 | 2007-09-14 | 이탈파마코 에스.피.에이. | Complex of paroxetine and cyclodextrin or cyclodextrin derivative |
| DE19930454A1 (en) * | 1999-07-02 | 2001-01-04 | Knoll Ag | Solid paroxetine-containing preparations |
| US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| ATE374602T1 (en) * | 2001-12-21 | 2007-10-15 | Supernus Pharmaceuticals Inc | ORAL CAPSULE FORMULATION WITH IMPROVED PHYSICAL STABILITY |
| SE0200475D0 (en) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral pharmaceutical preparation |
| WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
| US20120322752A1 (en) * | 2009-12-08 | 2012-12-20 | Sung Kyun Lee | SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| CN103961333B (en) * | 2014-05-07 | 2020-02-21 | 浙江华海药业股份有限公司 | Paroxetine mesylate capsule and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0818990A1 (en) * | 1995-04-03 | 1998-01-21 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
| EP0952831A1 (en) * | 1997-01-15 | 1999-11-03 | Smithkline Beecham Plc | Paroxetine compositions |
-
1997
- 1997-11-21 GB GBGB9724544.3A patent/GB9724544D0/en not_active Ceased
-
1998
- 1998-11-18 PE PE1998001126A patent/PE20000381A1/en not_active Application Discontinuation
- 1998-11-18 HU HU0100580A patent/HUP0100580A3/en unknown
- 1998-11-18 WO PCT/GB1998/003471 patent/WO1999026625A1/en not_active Ceased
- 1998-11-18 EA EA200000552A patent/EA200000552A1/en unknown
- 1998-11-18 AU AU11680/99A patent/AU1168099A/en not_active Abandoned
- 1998-11-18 JP JP2000521827A patent/JP2001523718A/en active Pending
- 1998-11-18 TR TR2000/01423T patent/TR200001423T2/en unknown
- 1998-11-18 EP EP98954631A patent/EP1033986A1/en not_active Withdrawn
- 1998-11-18 SK SK734-2000A patent/SK7342000A3/en unknown
- 1998-11-18 PL PL98340555A patent/PL340555A1/en unknown
- 1998-11-18 BR BR9814220-8A patent/BR9814220A/en not_active Application Discontinuation
- 1998-11-18 AP APAP/P/2000/001821A patent/AP2000001821A0/en unknown
- 1998-11-18 CN CN98811404A patent/CN1279608A/en active Pending
- 1998-11-18 KR KR1020007005532A patent/KR20010032320A/en not_active Withdrawn
- 1998-11-18 DZ DZ980268A patent/DZ2658A1/en active
- 1998-11-18 IL IL13610698A patent/IL136106A0/en unknown
- 1998-11-19 AR ARP980105880A patent/AR015485A1/en unknown
- 1998-11-19 MA MA25357A patent/MA24704A1/en unknown
- 1998-11-20 CO CO98068459A patent/CO4970832A1/en unknown
- 1998-11-20 ZA ZA9810637A patent/ZA9810637B/en unknown
-
2000
- 2000-05-19 NO NO20002590A patent/NO20002590L/en not_active Application Discontinuation
- 2000-05-19 OA OA1200000153A patent/OA11385A/en unknown
- 2000-06-13 BG BG104527A patent/BG104527A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002590D0 (en) | 2000-05-19 |
| EA200000552A1 (en) | 2000-10-30 |
| AP2000001821A0 (en) | 2000-06-30 |
| CO4970832A1 (en) | 2000-11-07 |
| HUP0100580A2 (en) | 2002-04-29 |
| WO1999026625A1 (en) | 1999-06-03 |
| MA24704A1 (en) | 1999-07-01 |
| ZA9810637B (en) | 2000-05-22 |
| PE20000381A1 (en) | 2000-05-07 |
| JP2001523718A (en) | 2001-11-27 |
| OA11385A (en) | 2004-01-27 |
| SK7342000A3 (en) | 2000-12-11 |
| CN1279608A (en) | 2001-01-10 |
| IL136106A0 (en) | 2001-05-20 |
| KR20010032320A (en) | 2001-04-16 |
| AU1168099A (en) | 1999-06-15 |
| DZ2658A1 (en) | 2003-03-22 |
| GB9724544D0 (en) | 1998-01-21 |
| EP1033986A1 (en) | 2000-09-13 |
| AR015485A1 (en) | 2001-05-02 |
| PL340555A1 (en) | 2001-02-12 |
| BR9814220A (en) | 2001-12-26 |
| HUP0100580A3 (en) | 2002-05-28 |
| BG104527A (en) | 2001-04-30 |
| TR200001423T2 (en) | 2000-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2191862T3 (en) | LIQUID COMPOSITION INCLUDING AN HIV PROTEASE INHIBITOR AND A FATTY ACID OF C12-C18. | |
| NO20002590L (en) | Formulations comprising dissolved paroxetine | |
| GB2314508A (en) | Diamide-dicarboxylic acid microspheres | |
| DE69927963D1 (en) | GELABLE PHARMACEUTICAL COMPOSITIONS | |
| NO20002133D0 (en) | Solid state solutions and dispersions of weakly water-soluble drugs | |
| ES2196621T3 (en) | ADMINISTRATION SYSTEMS OF PHARMACOS THAT USE LIQUID GLASS STRUCTURES. | |
| ATE215370T1 (en) | SELF-EMULSIFYING FORMULATION CONTAINING LIPOPHILIC COMPOUNDS | |
| DE69940674D1 (en) | ORAL ADMINISTRATION OF ADENOSINE ANALOG | |
| ES2035821T3 (en) | INTEGRATED DIRECTED ADMINISTRATION SYSTEM. | |
| FR2635265B1 (en) | INTRAVENOUS PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN AS ACTIVE INGREDIENT AND PROCESS FOR THE PREPARATION THEREOF | |
| DE58902457D1 (en) | RETARDED MEDICAL FORM AND METHOD FOR THE PRODUCTION THEREOF. | |
| ES8502333A1 (en) | Long-acting matrix tablet formulations. | |
| ES2029776T1 (en) | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING BROMOCRIPTINE WITH HIGH STABILITY. | |
| KR850001693A (en) | Method for preparing amosulolol hydrochloride long-acting formulation | |
| RU2000131588A (en) | PHARMACEUTICAL COMPOSITION | |
| AR013967A1 (en) | A DRUG FORMULATION FOR ORAL ADMINISTRATION OF CONTROLLED PELLET PELLET THAT HAS CONTROLLED RELEASE OF AN ACTIVE COMPOUND THAT IS SELECTED FROM THE ACID 1-CYCLOPROPIL-7- [(S, S) -2,8-DIAZABICICLO [4.3.0] NON- 8-IL] -6-FLUOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-CARBOXILIC QUINOLON OR SALE | |
| NO950134L (en) | Formulations for orally administered pharmaceutical agents | |
| DE3486020D1 (en) | SPIROTRICYCLOAROMATIC SUCCINIMID DERIVATIVES AS ALDOSE REDUCTASE INHIBITORS. | |
| NO931697L (en) | LHRH ANTAGONISTS | |
| FR2799660B1 (en) | SUPERCRITICAL FLUID EXTRACTION PROCESS | |
| EE03954B1 (en) | Method for the preparation of the carbamazepine sustained release dosage form | |
| Wiseman et al. | The distribution, excretion and metabolism of benzquinamide | |
| DE69830997D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING HEAVY-DIFFERENT MEDICAMENTS | |
| DK0624365T3 (en) | Pharmaceutical form for rectal administration of pharmacologically active compounds | |
| JPS55129220A (en) | Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |